Julie Green Sells 22,355 Shares of Invivyd (NASDAQ:IVVD) Stock

by · The Markets Daily

Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) insider Julie Green sold 22,355 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $16,095.60. Following the sale, the insider owned 187,362 shares of the company’s stock, valued at approximately $134,900.64. The trade was a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

  • On Tuesday, August 18th, Julie Green sold 18,425 shares of Invivyd stock. The stock was sold at an average price of $0.84, for a total value of $15,477.00.

Invivyd Stock Performance

Shares of NASDAQ IVVD traded up $0.13 during mid-day trading on Tuesday, reaching $0.87. The company had a trading volume of 7,732,095 shares, compared to its average volume of 3,061,089. Invivyd, Inc. has a one year low of $0.48 and a one year high of $3.07. The firm has a market cap of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The business’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $1.23.

Invivyd (NASDAQ:IVVD – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The firm had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. On average, sell-side analysts anticipate that Invivyd, Inc. will post -0.52 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. BTIG Research reissued a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. HC Wainwright restated a “buy” rating on shares of Invivyd in a research report on Tuesday. Finally, Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Get Our Latest Research Report on Invivyd

Invivyd News Roundup

Here are the key news stories impacting Invivyd this week:

  • Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
  • Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
  • Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IVVD. Eventide Asset Management LLC acquired a new stake in shares of Invivyd in the 4th quarter valued at approximately $14,349,000. Perceptive Advisors LLC bought a new stake in shares of Invivyd during the 4th quarter valued at approximately $53,809,000. BVF Inc. IL acquired a new position in Invivyd during the 4th quarter worth approximately $48,227,000. UBS Group AG increased its position in Invivyd by 683.8% during the 4th quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock worth $2,596,000 after purchasing an additional 916,842 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in Invivyd in the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

(Get Free Report)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

Recommended Stories